Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.rmcr.2017.05.014 http://scihub22266oqcxt.onion/10.1016/j.rmcr.2017.05.014 C5460743!5460743!28626631     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Respir+Med+Case+Rep 2017 ; 22 (ä): 11-4 Nephropedia Template TP {{tp|p=28626631|t=2017. Chronic eosinophilic pneumonia: Adjunctive therapy with inhaled steroids |pdf=|usr=}}{{28626631}} gab.com Text Chronic eosinophilic pneumonia: Adjunctive therapy with inhaled steroids JO: Respir Med Case Rep http://www.kidney.de/pget.php?&tw=1&pmid=28626631 #FOAvip Idiopathic chronic eosinophilic pneumonia (ICEP) is a rare form of diffuse parenchymal lung disease first identified by Carrington et al. in 1969. It is characterized by the presence of constitutional and respiratory symptoms with associated peripheral opacities on imaging and elevated serum and/or bronchoalveolar eosinophilia. Although data is limited regarding etiology or prevalence, it is known that ICEP has a 2:1 female: male predominance and typically affects non-smokers. Diagnosis rests on the clinical constellation of respiratory symptoms of at least 2?4 weeks duration, the presence of diffuse pulmonary alveolar consolidation, classically described as the ?photographic negative of pulmonary edema?, the presence of eosinophils ?40% on bronchoalveolar lavage or ?1000/mm3 eosinophils on peripheral blood and the exclusion of other known causes of eosinophilic lung diseases such as drugs, toxins, fungi, parasites, and collagen-vascular disorders. A dramatic response is achieved with systemic corticosteroids, which is typically dosed over 6 months to 1 year. Despite this response, approximately 30?50% of patients will relapse upon cessation of steroids or during the taper. Although these patients respond well to another trial of steroids, the side effects of long term steroids are well known, including osteoporosis, diabetes, hypertension and cataracts. Inhaled corticosteroids as monotherapy has been trialed in the past without success. However, we report a case of a patient who underwent treatment with systemic corticosteroids followed by inhaled steroids who has remained in remission for 2 years. Twit Text FOAVip Chronic eosinophilic pneumonia: Adjunctive therapy with inhaled steroids ????Respir Med Case Rep http://www.kidney.de/pget.php?&tw=1&pmid=28626631 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28626631 #FOAvip English Wikipedia <ref>{{Cite pmid|28626631}}</ref> Chronic eosinophilic pneumonia: Adjunctive therapy with inhaled steroids #MMPMID28626631 Chan C; DeLapp D; Nystrom P Respir Med Case Rep 2017[]; 22 (ä): 11-4 PMID28626631show ga Idiopathic chronic eosinophilic pneumonia (ICEP) is a rare form of diffuse parenchymal lung disease first identified by Carrington et al. in 1969. It is characterized by the presence of constitutional and respiratory symptoms with associated peripheral opacities on imaging and elevated serum and/or bronchoalveolar eosinophilia. Although data is limited regarding etiology or prevalence, it is known that ICEP has a 2:1 female: male predominance and typically affects non-smokers. Diagnosis rests on the clinical constellation of respiratory symptoms of at least 2?4 weeks duration, the presence of diffuse pulmonary alveolar consolidation, classically described as the ?photographic negative of pulmonary edema?, the presence of eosinophils ?40% on bronchoalveolar lavage or ?1000/mm3 eosinophils on peripheral blood and the exclusion of other known causes of eosinophilic lung diseases such as drugs, toxins, fungi, parasites, and collagen-vascular disorders. A dramatic response is achieved with systemic corticosteroids, which is typically dosed over 6 months to 1 year. Despite this response, approximately 30?50% of patients will relapse upon cessation of steroids or during the taper. Although these patients respond well to another trial of steroids, the side effects of long term steroids are well known, including osteoporosis, diabetes, hypertension and cataracts. Inhaled corticosteroids as monotherapy has been trialed in the past without success. However, we report a case of a patient who underwent treatment with systemic corticosteroids followed by inhaled steroids who has remained in remission for 2 years. äChronic eosinophilic pneumonia: Adjunctive therapy with inhaled steroi(epmc).pdf DeepDyve Pubget Overpricing